Medical Company Secures U.S. FDA Appeal For Marketing Authorization

U.S. FDA Revisits IceCure Medical's ProSense®: A Turning Point for Early-Stage Breast Cancer Treatment?

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant development that could revolutionize early-stage breast cancer treatment, the U.S. Food and Drug Administration (FDA) has granted an appeal to IceCure Medical Ltd., reopening the De Novo class…